Company Description
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States.
The company combines AI with scalable wet lab technologies to design differentiated antibody therapeutics.
Its integrated drug creation platform comprises AI models aimed at designing better antibody therapeutics, including against hard-to-drug targets, as well as improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit.
It has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, and Owkin for joint research and development activities.
The company was founded in 2011 and is headquartered in Vancouver, Washington.
Country | United States |
Founded | 2011 |
IPO Date | Jul 22, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 157 |
CEO | Sean McClain |
Contact Details
Address: 18105 SE Mill Plain Boulevard Vancouver, Washington 98683 United States | |
Phone | 360 949 1041 |
Website | absci.com |
Stock Details
Ticker Symbol | ABSI |
Exchange | NASDAQ |
Stock Type | Common Stock |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $16.00 |
CIK Code | 0001672688 |
CUSIP Number | 00091E109 |
ISIN Number | US00091E1091 |
Employer ID | 85-3383487 |
SIC Code | 8731 |
Key Executives
Name | Position |
---|---|
Sean McClain | Founder, Chief Executive Officer, President and Director |
Dr. Zachariah Jonasson Ph.D. | Chief Business Officer and Chief Financial Officer |
Dr. Andreas Busch Ph.D. | Chief Innovation Officer and Member of Scientific Advisory Board |
Todd Bedrick CPA | Senior Vice President and Chief Accounting Officer |
Alexander Khan CPA | Vice President of Finance and Head of Investor Relations |
Shelby Walker J.D. | Chief Legal Officer |
Karin Wierinck | Chief People Officer |
Melissa Patterson Ph.D. | Chief of Staff |
Wen Sha | Chief of Staff |
Dr. Christine Lemke D.V.M., M.B.A., Ph.D. | Senior Vice President of Portfolio and Growth Strategy |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 1, 2025 | S-3 | Registration statement under Securities Act of 1933 |
Mar 18, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
Mar 18, 2025 | 10-K | Annual Report |
Mar 18, 2025 | 8-K | Current Report |
Feb 19, 2025 | SCHEDULE 13G/A | Filing |
Feb 14, 2025 | SCHEDULE 13G/A | Filing |
Feb 14, 2025 | SCHEDULE 13G/A | Filing |
Jan 15, 2025 | 8-K | Current Report |
Jan 10, 2025 | SCHEDULE 13G | Filing |
Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |